V Sahai, MD, MS
@vsahaimd
GI Oncologist at Univ of Michigan. Opinions are mine.
ID: 53886385
https://scholar.google.com/scholar?hl=en&as_sdt=1,23&q=%22Vaibhav+Sahai%22&scisbd=1 05-07-2009 10:45:55
82 Tweet
309 Followers
90 Following
IMbrave150, unresctable HCC, impressive results and new standard of care....#ESMOAsia19 ESMO - Eur. Oncology
One of the most haunting pieces of journalism I have read in a while. It touches on colonial greed, displacement, mental illness, and creation of mythology. Do not miss this amazing piece by Ellen Barry in The New York Times nyti.ms/2s2AD8o
New in Journal of the @NCCN from Vaibhav Sahai & team: Oncologists doing tumor measurements in clinical trials may introduce significant variability & investigator bias. Institutional imaging cores may help bridge the gap, providing unbiased & reproducible measurements. jnccn.org/view/journals/ā¦
Work by Vaibhav Sahai and team featured by The Imaging Wire
'U-M Approach Could Improve the Accuracy of Cancer Clinical Trials labblog.uofmhealth.org/health-tech/u-ā¦ Who does tumor measurements for clinical trials at your center? Vaibhav Sahai Davendra Sohal Axel Grothey Heather McArthur, MD, MPH, FASCO Pashtoon Kasi MD, MS Davide Lo Conte Merry-Jennifer Markham, MD, FACP, FASCO Tatiana Prowell, MD Sumanta K. Pal, MD, FASCO Ivan Pedrosa Stephanie Graff, MD, FACP, FASCO
What is the role of immunotherapy for CHOLANGIOCARCINOMA? Vaibhav Sahai lead a trial of immunotherapy vs chemo-immunotherapy. Chemo-immunotherapy looks good, but did not beat the historical average. There are P3 trials looking at this combination, any predictions?
Shaalan Beg MD MBA FASCO Vaibhav Sahai Dustin Deming UTSW Simmons Cancer Center Cholangiocarcinoma Foundation Pashtoon Kasi MD, MS KModyMD Mike Pishvaian Rachna Shroff, MD, MS, FASCO Iām a data purist until Iām notš. Hoping we will find a way to use immunotherapy in #cholangiocarcinoma but we donāt know it yet. Thatās why Vaibhav Sahai and his #clinicaltrials are so important!
Laura Goff Shaalan Beg MD MBA FASCO Vaibhav Sahai Dustin Deming UTSW Simmons Cancer Center Cholangiocarcinoma Foundation Pashtoon Kasi MD, MS Mike Pishvaian Rachna Shroff, MD, MS, FASCO Yeah. And the Gem Cis Durva Treme data just seem too good to be true.
We are all coming to the same conclusion! TNT with predictive marker(s) to allow therapy switching. Our next trial at UC Health is exactly that...an adaptive design. Ultimately better drugs needed. Syed A. Ahmad Susan Tsai, MD, MHS Rachna Shroff, MD, MS, FASCO Ben Westphalen Bassam Estfan
Outstanding poster discussion by Dr. Katie Kelley...head spinning gleefully with all of the advancements in hepaobiliary cancers! UCSF Helen Diller Family Comprehensive Cancer Ctr Vaibhav Sahai Rachna Shroff, MD, MS, FASCO Autumn Shaalan Beg MD MBA FASCO Dustin Deming Kristen Ciombor Dana Cardin, MD Rajiv Agarwal MD @nanudasmd @VUMC_Cancer
After 19 years, Iāve left Stanford. The accumulated gender discrimination and harassment had taken their toll. I shared my story with Kate Selig and The Stanford Daily because I think it is important and hope it will empower others to speak up. THREAD 1/ stanforddaily.com/2020/06/10/desā¦
"The 2:1 randomized phase 2 part of the trial... will now determine the efficacy of devimistat at this maximum tolerated dose in combination with gemcitabine and cisplatin as compared with the combination chemotherapy alone,ā says #RogelCancer's V Sahai, MD, MS. targetedonc.com/view/devimistaā¦
The $100 genome via Ultima Genomics techcrunch.com/2022/05/31/ultā¦
#ASCO22 #PancreaticCancer š¤Is more betterā ā Dr. Carratoš§āš«a Rand trial šGem-nab-pacā”ļøFOLFOX (sequenced Q6 wks) vs. šStandard Gem-nab-pac ā”ļømOS was 3.5mosā¬ļøwith sequenced Tx ā”ļøEven though more standard pts got 2nd line Tx š¤ÆReallyā š¤Interesting šGI Can Oral Abst 4022
Overview of the novel autophagy inhibitor PIKfyve presented by Dr. Vaibhav Sahai V Sahai, MD, MS from University of Michigan: targeting cellular processes to combat malignancies! #DAVAGI
